

Amalia Azzariti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5338757/publications.pdf>

Version: 2024-02-01

135
papers

3,468
citations

94433

37
h-index

168389

53
g-index

142
all docs

142
docs citations

142
times ranked

6291
citing authors

#	ARTICLE	IF	CITATIONS
1	Cytochrome c Is Released from Mitochondria in a Reactive Oxygen Species (ROS)-dependent Fashion and Can Operate as a ROS Scavenger and as a Respiratory Substrate in Cerebellar Neurons Undergoing Excitotoxic Death. <i>Journal of Biological Chemistry</i> , 2000, 275, 37159-37166.	3.4	187
2	The complexity of targeting EGFR signalling in cancer: From expression to turnover. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2006, 1766, 120-139.	7.4	142
3	The NHERF1 PDZ2 Domain Regulates PKAâ€“RhoAâ€“p38-mediated NHE1 Activation and Invasion in Breast Tumor Cells. <i>Molecular Biology of the Cell</i> , 2007, 18, 1768-1780.	2.1	121
4	Plasma-activated medium triggers cell death and the presentation of immune activating danger signals in melanoma and pancreatic cancer cells. <i>Scientific Reports</i> , 2019, 9, 4099.	3.3	112
5	Cyclohexylpiperazine derivative PB28, a Î²2 agonist and Î²1 antagonist receptor, inhibits cell growth, modulates P-glycoprotein, and synergizes with anthracyclines in breast cancer. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1807-1816.	4.1	108
6	Hepatic stellate cells induce hepatocellular carcinoma cell resistance to sorafenib through the lamininâ€“32/Î±3 integrin axis recovery of focal adhesion kinase ubiquitination. <i>Hepatology</i> , 2016, 64, 2103-2117.	7.3	80
7	Small P-gp modulating molecules: SAR studies on tetrahydroisoquinoline derivatives. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 362-373.	3.0	78
8	CAFs and TGF-Î² Signaling Activation by Mast Cells Contribute to Resistance to Gemcitabine/Nabpaclitaxel in Pancreatic Cancer. <i>Cancers</i> , 2019, 11, 330.	3.7	71
9	The effect of gefitinib (Iressa, ZD1839) in combination with oxaliplatin is schedule-dependent in colon cancer cell lines. <i>Cancer Chemotherapy and Pharmacology</i> , 2003, 52, 442-448.	2.3	67
10	Gene Expression Comparison between the Lymph Node-Positive and -Negative Reveals a Peculiar Immune Microenvironment Signature and a Theranostic Role for WNT Targeting in Pancreatic Ductal Adenocarcinoma: A Pilot Study. <i>Cancers</i> , 2019, 11, 942.	3.7	66
11	MicroRNA in pancreatic adenocarcinoma: predictive/prognostic biomarkers or therapeutic targets?. <i>Oncotarget</i> , 2015, 6, 23323-23341.	1.8	65
12	Laminin-5 stimulates hepatocellular carcinoma growth through a different function of Î±6Î²4 and Î±3Î²1 integrins. <i>Hepatology</i> , 2007, 46, 1801-1809.	7.3	63
13	Carcinogenesis of Pancreatic Adenocarcinoma: Precursor Lesions. <i>International Journal of Molecular Sciences</i> , 2013, 14, 19731-19762.	4.1	59
14	Targeting human liver cancer cells with lactobionic acid-G(4)-PAMAM-FITC sorafenib loaded dendrimers. <i>International Journal of Pharmaceutics</i> , 2017, 528, 485-497.	5.2	57
15	Natural History of Malignant Bone Disease in Gastric Cancer: Final Results of a Multicenter Bone Metastasis Survey. <i>PLoS ONE</i> , 2013, 8, e74402.	2.5	56
16	Circulating extracellular vesicles expressing PD1 and PD-L1 predict response and mediate resistance to checkpoint inhibitors immunotherapy in metastatic melanoma. <i>Molecular Cancer</i> , 2022, 21, 20.	19.2	55
17	The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839). <i>Biochemical Pharmacology</i> , 2004, 68, 135-144.	4.4	54
18	4-Biphenyl and 2-naphthyl substituted 6,7-dimethoxytetrahydroisoquinoline derivatives as potent P-gp modulators. <i>Bioorganic and Medicinal Chemistry</i> , 2008, 16, 3732-3743.	3.0	54

#	ARTICLE	IF	CITATIONS
19	Optimize radiochemotherapy in pancreatic cancer: PARP inhibitors a new therapeutic opportunity. <i>Molecular Oncology</i> , 2013, 7, 308-322.	4.6	54
20	Sorafenib delivery nanoplatform based on superparamagnetic iron oxide nanoparticles magnetically targets hepatocellular carcinoma. <i>Nano Research</i> , 2017, 10, 2431-2448.	10.4	54
21	Aurora B kinase inhibitor AZD1152: determinants of action and ability to enhance chemotherapeutics effectiveness in pancreatic and colon cancer. <i>British Journal of Cancer</i> , 2011, 104, 769-780.	6.4	52
22	Sigma α 2 Receptor Agonists as Possible Antitumor Agents in Resistant Tumors: Hints for Collateral Sensitivity. <i>ChemMedChem</i> , 2013, 8, 2026-2035.	3.2	52
23	Laminin-5 offsets the efficacy of gefitinib (Iressa TM) in hepatocellular carcinoma cells. <i>British Journal of Cancer</i> , 2004, 91, 1964-1969.	6.4	50
24	Characterization of sequence-dependent synergy between ZD1839 (Iressa TM) and oxaliplatin. <i>Biochemical Pharmacology</i> , 2003, 66, 551-563.	4.4	48
25	EGFR and VEGFR as potential target for biological therapies in HCC cells. <i>Cancer Letters</i> , 2008, 262, 257-264.	7.2	48
26	Preferential chemosensitization of PTEN-mutated prostate cells by silencing the Akt kinase. <i>Prostate</i> , 2007, 67, 782-789.	2.3	47
27	Synergic antiproliferative and antiangiogenic effects of EGFR and mTor inhibitors on pancreatic cancer cells. <i>Biochemical Pharmacology</i> , 2008, 75, 1035-1044.	4.4	47
28	Targeting Angiogenesis in Biliary Tract Cancers: An Open Option. <i>International Journal of Molecular Sciences</i> , 2017, 18, 418.	4.1	47
29	Synthesis, Characterization and Biological Evaluation of Ureidofibrate-Like Derivatives Endowed with Peroxisome Proliferator-Activated Receptor Activity. <i>Journal of Medicinal Chemistry</i> , 2012, 55, 37-54.	6.4	46
30	Tyrosine kinase inhibitors and multidrug resistance proteins: interactions and biological consequences. <i>Cancer Chemotherapy and Pharmacology</i> , 2010, 65, 335-346.	2.3	45
31	Coexpression of CD133 ⁺ /CD44 ⁺ in human colon cancer and liver metastasis. <i>Journal of Cellular Physiology</i> , 2013, 228, 408-415.	4.1	45
32	Strategies to Improve Cancer Immune Checkpoint Inhibitors Efficacy, Other Than Abscopal Effect: A Systematic Review. <i>Cancers</i> , 2019, 11, 539.	3.7	45
33	Dissecting the Potential Roles of Nigella sativa and Its Constituent Thymoquinone on the Prevention and on the Progression of Alzheimer's Disease. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 16.	3.4	44
34	Target Therapies in Pancreatic Carcinoma. <i>Current Medicinal Chemistry</i> , 2014, 21, 948-965.	2.4	43
35	Kinase activation profile associated with TGF- β -dependent migration of HCC cells: a preclinical study. <i>Cancer Chemotherapy and Pharmacology</i> , 2011, 68, 79-86.	2.3	42
36	The clinical development of inhibitors of poly(ADP-ribose) polymerase. <i>Annals of Oncology</i> , 2011, 22, i53-i59.	1.2	42

#	ARTICLE	IF	CITATIONS
37	EGFR tyrosine kinases inhibitors in cancer treatment: in vitro and in vivo evidence. <i>Frontiers in Bioscience - Landmark</i> , 2011, 16, 1962.	3.0	42
38	EGFR mutations and HER2/3 protein expression and clinical outcome in Chinese advanced non-small cell lung cancer patients treated with gefitinib. <i>Journal of Cancer Research and Clinical Oncology</i> , 2009, 135, 771-782.	2.5	38
39	ZD6474 inhibits proliferation and invasion of human hepatocellular carcinoma cells. <i>Biochemical Pharmacology</i> , 2006, 71, 479-485.	4.4	36
40	PI3K class IB controls the cell cycle checkpoint promoting cell proliferation in hepatocellular carcinoma. <i>International Journal of Cancer</i> , 2012, 130, 2505-2513.	5.1	36
41	Aurora kinase B inhibition reduces the proliferation of metastatic melanoma cells and enhances the response to chemotherapy. <i>Journal of Translational Medicine</i> , 2015, 13, 26.	4.4	34
42	Interaction of the β Receptor Ligand PB28 with the Human Nucleosome: Computational and Experimental Probes of Interaction with the H2A/H2B Dimer. <i>ChemMedChem</i> , 2010, 5, 268-273.	3.2	32
43	Tumor endothelial markers as a target in cancer. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, 1215-1225.	3.4	28
44	MicroRNA expression in BRAF-mutated and wild-type metastatic melanoma and its correlation with response duration to BRAF inhibitors. <i>Expert Opinion on Therapeutic Targets</i> , 2015, 19, 1027-1035.	3.4	27
45	New insight into the role of metabolic reprogramming in melanoma cells harboring BRAF mutations. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2016, 1863, 2710-2718.	4.1	27
46	Intracellular Trafficking of MDR Transporters and Relevance of SNPs. <i>Current Topics in Medicinal Chemistry</i> , 2009, 9, 197-208.	2.1	25
47	Prolonged exposure of colon cancer cells to the epidermal growth factor receptor inhibitor gefitinib (Iressa [®]) and to the antiangiogenic agent ZD6474: Cytotoxic and biomolecular effects. <i>World Journal of Gastroenterology</i> , 2006, 12, 5140.	3.3	25
48	miRNAs for the Detection of MultiDrug Resistance: Overview and Perspectives. <i>Molecules</i> , 2014, 19, 5611-5623.	3.8	24
49	The HMGA1 Pseudogene 7 Induces miR-483 and miR-675 Upregulation by Activating Egr1 through a ceRNA Mechanism. <i>Genes</i> , 2017, 8, 330.	2.4	24
50	Trimethoxybenzanilide-Based P-Glycoprotein Modulators: An Interesting Case of Lipophilicity Tuning by Intramolecular Hydrogen Bonding. <i>Journal of Medicinal Chemistry</i> , 2014, 57, 6403-6418.	6.4	23
51	uPAR ⁺ extracellular vesicles: a robust biomarker of resistance to checkpoint inhibitor immunotherapy in metastatic melanoma patients. , 2021, 9, e002372.		23
52	The EGFR Pathway Regulates BCRP Expression in NSCLC Cells: Role of Erlotinib. <i>Current Drug Targets</i> , 2014, 15, 1322-1330.	2.1	23
53	Microfluidic preparation and in vitro evaluation of iRGD-functionalized solid lipid nanoparticles for targeted delivery of paclitaxel to tumor cells. <i>International Journal of Pharmaceutics</i> , 2021, 610, 121246.	5.2	23
54	Antitumor Potential of Conjugable Valinomycins Bearing Hydroxyl Sites: In Vitro Studies. <i>ACS Medicinal Chemistry Letters</i> , 2013, 4, 1189-1192.	2.8	22

#	ARTICLE	IF	CITATIONS
55	Irradiation-induced angiosarcoma and anti-angiogenic therapy: A therapeutic hope?. <i>Experimental Cell Research</i> , 2014, 321, 240-247.	2.6	21
56	Enhancing the biological activity of polyoxometalate-peptide nano-fibrils by spacer design. <i>RSC Advances</i> , 2021, 11, 4952-4957.	3.6	21
57	The Impact of Folate Status on the Efficacy of Colorectal Cancer Treatment. <i>Current Drug Metabolism</i> , 2011, 12, 975-984.	1.2	19
58	Synthesis, Characterization, and Cytotoxicity of the First Oxaliplatin Pt(IV) Derivative Having a TSPO Ligand in the Axial Position. <i>International Journal of Molecular Sciences</i> , 2016, 17, 1010.	4.1	19
59	Synthetic Lethality to Overcome Cancer Drug Resistance. <i>Current Medicinal Chemistry</i> , 2012, 19, 3858-3873.	2.4	18
60	Sporadic melanoma in South-Eastern Italy: the impact of melanocortin 1 receptor (MC1R) polymorphism analysis in low-risk people and report of three novel variants. <i>Archives of Dermatological Research</i> , 2015, 307, 495-503.	1.9	18
61	Tomatine Displays Antitumor Potential in In Vitro Models of Metastatic Melanoma. <i>International Journal of Molecular Sciences</i> , 2020, 21, 5243.	4.1	18
62	The β -adrenergic receptor antagonist propranolol offsets resistance mechanisms to chemotherapeutics in diverse sarcoma subtypes: a pilot study. <i>Scientific Reports</i> , 2020, 10, 10465.	3.3	18
63	The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy. <i>Current Drug Metabolism</i> , 2011, 12, 713-721.	1.2	17
64	Magnetic implants in vivo guiding sorafenib liver delivery by superparamagnetic solid lipid nanoparticles. <i>Journal of Colloid and Interface Science</i> , 2022, 608, 239-254.	9.4	17
65	The Role of Non-Coding RNAs as Prognostic Factor, Predictor of Drug Response or Resistance and Pharmacological Targets, in the Cutaneous Squamous Cell Carcinoma. <i>Cancers</i> , 2020, 12, 2552.	3.7	16
66	Active notch protects MAPK activated melanoma cell lines from MEK inhibitor cobimetinib. <i>Biomedicine and Pharmacotherapy</i> , 2021, 133, 111006.	5.6	16
67	Frizzled-10 and cancer progression: Is it a new prognostic marker?. <i>Oncotarget</i> , 2018, 9, 824-830.	1.8	16
68	Update on capecitabine alone and in combination regimens in colorectal cancer patients. <i>Cancer Treatment Reviews</i> , 2010, 36, S46-S55.	7.7	15
69	A new generation of MDR modulating agents with dual activity: P-gp inhibitor and iNOS inducer agents. <i>Toxicology in Vitro</i> , 2011, 25, 222-230.	2.4	15
70	The interaction of celecoxib with MDR transporters enhances the activity of mitomycin C in a bladder cancer cell line. <i>Molecular Cancer</i> , 2013, 12, 47.	19.2	15
71	Proteomic Profile and In Silico Analysis in Metastatic Melanoma with and without BRAF Mutation. <i>PLoS ONE</i> , 2014, 9, e112025.	2.5	15
72	Behind the Scene: Exploiting MC1R in Skin Cancer Risk and Prevention. <i>Genes</i> , 2021, 12, 1093.	2.4	15

#	ARTICLE	IF	CITATIONS
73	The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: a phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale). <i>BMC Cancer</i> , 2018, 18, 552.	2.6	14
74	Optimized granulocyte colony-stimulating factor prophylaxis in adult cancer patients: from biological principles to clinical guidelines. <i>Expert Opinion on Therapeutic Targets</i> , 2012, 16, S111-S117.	3.4	13
75	Expression of proteins involved in DNA damage response in familial and sporadic breast cancer patients. <i>International Journal of Cancer</i> , 2016, 138, 110-120.	5.1	13
76	Phosphatidylinositol 3-Kinase in Breast Cancer: Where from Here?. <i>Clinical Cancer Research</i> , 2007, 13, 5988-5990.	7.0	12
77	p53 as the main traffic controller of the cell signaling network. <i>Frontiers in Bioscience - Landmark</i> , 2010, 15, 1172.	3.0	12
78	Melanoma and immunotherapy bridge 2015. <i>Journal of Translational Medicine</i> , 2016, 14, 65.	4.4	12
79	Microfluidic-Assisted Preparation of Targeted pH-Responsive Polymeric Micelles Improves Gemcitabine Effectiveness in PDAC: In Vitro Insights. <i>Cancers</i> , 2022, 14, 5.	3.7	12
80	Pharmacokinetic and Metabolism Determinants of Fluoropyrimidines and Oxaliplatin Activity in Treatment of Colorectal Patients. <i>Current Drug Metabolism</i> , 2011, 12, 918-931.	1.2	11
81	Combination of 5-Fluorouracil and Irinotecan on Modulation of Thymidylate Synthase and Topoisomerase I Expression and Cell Cycle Regulation in Human Colon Cancer LoVo Cells: Clinical Relevance. <i>Clinical Colorectal Cancer</i> , 2002, 2, 182-188.	2.3	10
82	MC70 potentiates doxorubicin efficacy in colon and breast cancer in vitro treatment. <i>European Journal of Pharmacology</i> , 2011, 670, 74-84.	3.5	10
83	The ERR α -VDR axis promotes calcitriol degradation and estrogen signaling in breast cancer cells, while VDR α -CYP24A1 α overexpression correlates with poor prognosis in patients with basal-like breast cancer. <i>Molecular Oncology</i> , 2022, 16, 904-920.	4.6	10
84	Synergistic Antiproliferative and Antiangiogenic Effects of EGFR and mTOR Inhibitors. <i>Current Pharmaceutical Design</i> , 2013, 19, 918-926.	1.9	9
85	Metastatic melanoma cells with BRAF G469A mutation: nab-paclitaxel better than vemurafenib?. <i>Cancer Chemotherapy and Pharmacology</i> , 2015, 76, 433-438.	2.3	9
86	Potential predictive role of chemotherapy-induced changes of soluble CD40 ligand in untreated advanced pancreatic ductal adenocarcinoma. <i>OncoTargets and Therapy</i> , 2016, Volume 9, 4681-4686.	2.0	9
87	The Interaction between Reactive Peritoneal Mesothelial Cells and Tumor Cells via Extracellular Vesicles Facilitates Colorectal Cancer Dissemination. <i>Cancers</i> , 2021, 13, 2505.	3.7	9
88	Grape seed extracts modify the outcome of oxaliplatin in colon cancer cells by interfering with cellular mechanisms of drug cytotoxicity. <i>Oncotarget</i> , 2017, 8, 50845-50863.	1.8	9
89	Kinetic properties and thermal stabilities of mutant forms of mitochondrial aspartate aminotransferase. <i>BBA - Proteins and Proteomics</i> , 1998, 1386, 29-38.	2.1	8
90	Detrimental effects of melanocortin α receptor (MC1R) variants on the clinical outcomes of BRAF V600 metastatic melanoma patients treated with BRAF inhibitors. <i>Pigment Cell and Melanoma Research</i> , 2016, 29, 679-687.	3.3	8

#	ARTICLE	IF	CITATIONS
91	Translational control mechanisms in cutaneous malignant melanoma: the role of eIF2 $\hat{\pm}$. Journal of Translational Medicine, 2019, 17, 20.	4.4	8
92	Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer. World Journal of Gastroenterology, 2016, 22, 6287.	3.3	8
93	BRAFV600E;K601Q metastatic melanoma patient-derived organoids and docking analysis to predict the response to targeted therapy. Pharmacological Research, 2022, 182, 106323.	7.1	8
94	Targeting EGFR in bilio-pancreatic and liver carcinoma. Frontiers in Bioscience - Scholar, 2011, S3, 16-22.	2.1	7
95	Synthesis and biological evaluation of N-biphenyl-nicotinic based moiety compounds: A new class of antimetabolic agents for the treatment of Hodgkin Lymphoma. Cancer Letters, 2019, 445, 1-10.	7.2	7
96	New Vascular Disrupting Agents in Upper Gastrointestinal Malignancies. Current Medicinal Chemistry, 2014, 21, 1039-1049.	2.4	7
97	Nti-EGFR monoclonal antibody in cancer treatment: in vitro and in vivo evidence. Frontiers in Bioscience - Landmark, 2011, 16, 1973.	3.0	7
98	Extracellular ADP prevents neuronal apoptosis via activation of cell antioxidant enzymes and protection of mitochondrial ANT-1. Biochimica Et Biophysica Acta - Bioenergetics, 2014, 1837, 1338-1349.	1.0	6
99	The next generation of metastatic melanoma: uncovering the genetic variants for anti-BRAF therapy response. Oncotarget, 2016, 7, 25135-25149.	1.8	6
100	The Genetic Germline Background of Single and Multiple Primary Melanomas. Frontiers in Molecular Biosciences, 2020, 7, 555630.	3.5	6
101	Predictive factors to targeted treatment in gastrointestinal carcinomas. Cancer Biomarkers, 2014, 14, 151-162.	1.7	5
102	The N-Terminal Region of Mature Mitochondrial Aspartate Aminotransferase Can Direct Cytosolic Dihydrofolate Reductase into Mitochondria in Vitro. Biochemical and Biophysical Research Communications, 1994, 201, 1059-1065.	2.1	4
103	Probing the interaction between cisplatin and the therapeutic monoclonal antibody trastuzumab. RSC Advances, 2016, 6, 29229-29236.	3.6	4
104	Hydroxy-Propyl- $\hat{\beta}$ -Cyclodextrin Inclusion Complexes of two Biphenylnicotinamide Derivatives: Formulation and Anti-Proliferative Activity Evaluation in Pancreatic Cancer Cell Models. International Journal of Molecular Sciences, 2020, 21, 6545.	4.1	4
105	New Oxaliplatin-Pyrophosphato Analogs with Improved In Vitro Cytotoxicity. Molecules, 2021, 26, 3417.	3.8	4
106	The Pharmaceutical Technology Approach on Imaging Innovations from Italian Research. Pharmaceutics, 2021, 13, 1214.	4.5	4
107	Natural Bovine Coronavirus Infection in a Calf Persistently Infected with Bovine Viral Diarrhea Virus: Viral Shedding, Immunological Features and S Gene Variations. Animals, 2021, 11, 3350.	2.3	4
108	Validation of gefitinib effectiveness in a broad panel of head and neck squamous carcinoma cells. International Journal of Molecular Medicine, 2008, 21, 809-17.	4.0	3

#	ARTICLE	IF	CITATIONS
109	Mitochondrial impairment induces excitotoxic death in cerebellar granule cells. <i>International Journal of Molecular Medicine</i> , 2004, 13, 873.	4.0	2
110	Salting-Out Approach Is Worthy of Comparison with Ultracentrifugation for Extracellular Vesicle Isolation from Tumor and Healthy Models. <i>Biomolecules</i> , 2021, 11, 1857.	4.0	2
111	Cumulative Effects of Mutations in Newly Synthesized Mitochondrial Aspartate Aminotransferase on Uptake into Mitochondria. <i>Biochemical and Biophysical Research Communications</i> , 1995, 214, 511-517.	2.1	1
112	The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa?, ZD1839). <i>Biochemical Pharmacology</i> , 2004, 68, 135-135.	4.4	1
113	P27 Antiangiogenic activity of combining gefitinib and rapamycin in a panel of pancreas cancer cell lines. <i>European Journal of Cancer, Supplement</i> , 2007, 5, 31.	2.2	1
114	275 SORAFENIB EFFECTIVENESS IS INHIBITED IN PRESENCE OF LAMININ-5 IN HCC CELLS. <i>Journal of Hepatology</i> , 2012, 56, S114.	3.7	1
115	Possible role of vascular endothelial growth factor (VEGF) levels in immunodepleted plasma of metastatic colorectal cancer (mCRC) patients (pts) treated with a biweekly administration of capecitabine plus oxaliplatin (XELOX-2) plus bevacizumab: Preliminary results.. <i>Journal of Clinical Oncology</i> , 2011, 29, e14155-e14155.	1.6	1
116	Use of Protease Sensitivity to Probe the Conformations of Newly Synthesized Mutant Forms of Mitochondrial Aspartate Aminotransferase. <i>Biochemical and Biophysical Research Communications</i> , 1995, 215, 800-807.	2.1	0
117	257 An inhibitor of VEGF(ZD6474) as a potential new drug for HCC: A preclinical study. <i>Journal of Hepatology</i> , 2006, 44, S102.	3.7	0
118	Correction: Article on Phosphatidylinositol 3-Kinase in Breast Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 1281-1281.	7.0	0
119	34 AZD1152 PLUS GEMCITABINE FOR PANCREAS CANCER TREATMENT: IN VITRO AND IN VIVO STUDY. <i>Cancer Treatment Reviews</i> , 2010, 36, S105.	7.7	0
120	46 IS BCRP EXPRESSION AND LOCALIZATION REGULATED BY EGFR PATHWAY IN NSCLC CELLS?. <i>Cancer Treatment Reviews</i> , 2010, 36, S108.	7.7	0
121	47 BIOLOGICAL CHARACTERIZATION OF MC70, AS POTENT INHIBITOR OF ABC TRANSPORTERS INVOLVED IN MULTIDRUG RESISTANCE. <i>Cancer Treatment Reviews</i> , 2010, 36, S109.	7.7	0
122	214 PI3K CLASS 1B CONTROLS THE CELL CYCLE CHECKPOINT AT THE G2/M PHASE PROMOTING CELL PROLIFERATION IN HEPATOCELLULAR CARCINOMA. <i>Journal of Hepatology</i> , 2011, 54, S90.	3.7	0
123	Editorial [Hot Topic: Biomarkers of Chemotherapeutics Efficacy and Toxicity in Colorectal Cancer (Guest Editor: Amalia Azzariti)]. <i>Current Drug Metabolism</i> , 2011, 12, 917-917.	1.2	0
124	1044 LYSOPHOSPHATIDIC ACID RECEPTOR 6 (LPA6) PROMOTES HEPATOCELLULAR CARCINOMA GROWTH AND PROGRESSION THROUGH ACTIVATION OF PIM-3 PROTO-ONCOGENE KINASE. <i>Journal of Hepatology</i> , 2013, 58, S429.	3.7	0
125	Editorial (Thematic Issue: Targeted Therapies in Upper Gastrointestinal Malignancies). <i>Current Medicinal Chemistry</i> , 2014, 21, 947-947.	2.4	0
126	844: A novel strategy for the treatment of Hodgkin lymphoma. <i>European Journal of Cancer</i> , 2014, 50, S205.	2.8	0

#	ARTICLE	IF	CITATIONS
127	P74 LAMININ-5 INDUCES RESISTANCE TO SORAFENIB IN HCC PRECLINICAL MODELS. Journal of Hepatology, 2014, 60, S91.	3.7	0
128	Sequential combination of low dose chemo-modulating Temozolomide and Fotemustine in metastatic melanoma: clinical and molecular evaluation. Annals of Oncology, 2015, 26, vi26.	1.2	0
129	Negative influence of Melanocortin-1 receptor (MC1R) polymorphisms on clinical outcomes of metastatic melanoma (MM) patients (pts) harboring BRAF mutation and treated with BRAF inhibitors (BRAFi). Annals of Oncology, 2015, 26, vi26.	1.2	0
130	Mast Cells (MCs) Infiltration Affects Pancreatic Cancer (PC) Response To Gemcitabine Based Chemotherapy: In Vitro New Insights. Annals of Oncology, 2015, 26, vi101.	1.2	0
131	Possible predictive role of the soluble cd40 ligand (scd40l) in metastatic pancreatic ductal adenocarcinoma (PDAC) patients (pts) treated with first line folfirinox or gemcitabine/nab-paclitaxel combination. Annals of Oncology, 2015, 26, vi99.	1.2	0
132	Potential therapeutic combination of beta-blockers and trabectedin in metastatic soft tissue sarcoma and ovarian cancer. Annals of Oncology, 2017, 28, vi66-vi67.	1.2	0
133	High-Throughput Analysis of the Drug Mode of Action of PB28, MC18 and MC70, Three Cyclohexylpiperazine Derivative New Molecules. Lecture Notes in Computer Science, 2008, , 1085-1092.	1.3	0
134	Influence of melanocortin-1 receptor (MC1R) polymorphisms on clinical outcomes of patients with metastatic melanoma harboring the BRAF mutation and treated with BRAF inhibitors.. Journal of Clinical Oncology, 2016, 34, 9574-9574.	1.6	0
135	Abstract 2238: Synergistic effect of sunitinib and PD-1 inhibitor nivolumab on colorectal cancerin vitroandin vivo. , 2020, , .		0